Skip to main
CING
CING logo

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc has significantly strengthened its balance sheet, which positions the company favorably for future growth and market opportunities. The positive outcome of a Phase 3 study for CTx-1301, evidenced by an industry-leading average effect size of 1.79 compared to the 0.73 average of marketed ADHD drugs, bolsters its potential market competitiveness. Additionally, the increased probability of approval for CTx-1301 to 75%, supported by the FDA's recognition of leveraging existing data, underscores the promising outlook for Cingulate's innovative product pipeline.

Bears say

Cingulate Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from potential delays in the development and regulatory approval process for its product CTx-1301. The company may encounter challenges such as slower market uptake and lower-than-expected penetration rates for CTx-1301 in the ADHD segment, along with partnership risks related to its relationship with Indegene. Additionally, there is a looming threat of dilution in the near to medium term, further complicating the company’s financial position amidst a mature ADHD market environment reflected by a 12% discount rate.

Cingulate (CING) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.